Microfloppies Systems Have Potential to Help Millions of Diabetics
microfloppies while “nanotechnology” has been a common buzzword among investors. Researchers, “nanotechnology” has graduate, from university research laboratories into commercial reality. MEMS (Small Electromagnetically System) technology has been around since the late 1970s . Saw a massive increase in popularity in the 1990s in the telecommunications industry. Because it could be use to make optical fiber switches at a microfloppies microscopic scale.
microfloppies the industry sees benefits
Recently, the pharmaceutical medical equipment industry, has realize the benefits of microelectronic, microfloppies systems. Which has led to the development of a whole new industry, of microfloppies drug delivery systems. Although many drugs are use in microfloppies systems, insulin is what attracts both consumers and the industry the most, to diabetics. With the rise in insulin-dependent diabetes.
There is a large market for painless implantable robotic insulin devices. That provide accurate doses base on patient needs that are automatically detect. As always, these devices have to be inexpensive. So which means that the MEMs manufacturing process must be able to mass-produce. Something that has been a challenge until recently.
Composition of microfloppies systems
Microfloppies drug delivery systems have three main components. Needle set, pump, valve system, and chemical sensors. A needle group usually consists of hundreds of needles drill with, a microscopic, silicon wafer with holes for the drug to pass through. Since these needles are so small. As per they are painless and yet deliver a large amount of the substance right away.
Integrated solutions are showing promise
Market leaders in microfloppies insulin pumps such as ISSYS, Exigent. Biotech and Biophys focus on integrate solutions that can be mass-produce. They understand that the key to success is inexpensively providing a complete system that can be implant in an outpatient setting, monitor the sensors in the sensor system, and refill with insulin by the patient.
The market for microfloppies insulin pumps is expect to reach 2 billion DKK. The dollar in 2010 with significant continuous growth over the next ten years.
Breast cancer, blood cells, and pacemakers
The biochemical signals that control, breast cancer cell migration are poorly understood. But new microfloppies devices specifically design to track. How breast cancer cells move in response to chemical signals are in development. This will allow doctors to reduce the amount of toxicity drugs.
So that are given to the patient and allow. These drugs to target only cancer cells, rather. So than the cells they are in contact with. For women with breast cancer. per so this can mean an end to hair loss, debilitating fatigue. Other harmful side effects associate with chemotherapy.
The possibilities seem endless
For the medical equipment industry, so this is a wake-up call to search for MEM and MICS solutions to the major problems we face in the United States. as per With the increasing epidemics of obesity, diabetes, heart disease and cancer,
there are countless opportunities for companies large. Small to develop sensor-base diagnostic. Treatment devices that help patients live longer. healthier lives with less invasive procedures.